NY-GARIA
5.10.2021 16:55:09 CEST | Business Wire | Press release
Viridi Parente, Inc., a developer of innovative battery technology that can be safely installed and operated in nearly any environment or location, is partnering with Garia Utility , the Denmark-based leader in low-speed utility vehicles , to develop last-mile , low-speed electric utility vehicles for the U.S. market. These vehicles will be manufactured in Buffalo, New York, and branded under the Green Machine Equipment name.
An image of the Green Machine electric, low-speed utility vehicle may be downloaded here - https://rb.gy/uywc9e .
"If we are going to have any impact on decarbonization, we need to rethink our supply chain strategies and equipment options, especially for last-mile delivery," said Jon M. Williams, CEO of Viridi Parente. "Green Machine couldn't ask for a better partner to introduce clean utility vehicles into the U.S. than Garia. Its proven technology is already deployed throughout Europe, and the compact design is ideally suited for use in dense, urban areas in the U.S."
Garia chose to partner with Green Machine because of its proprietary, durable, and safe battery technology that is being used by leading construction brands such as Bobcat and Case . Green Machine was the first manufacturer to introduce all-electric heavy construction and industrial equipment into the market and has perfected the technology with more than 250,000 hours of robust field testing.
Garia Utility has over 900 last-mile vehicles deployed on delivery routes in Sweden through a contract with PostNord (the Swedish Postal Service). The combination of Green Machine's propriety technology and Garia's know-how in the last-mile vehicle space creates a superb clean vehicle that replaces standard diesel or gasoline-powered utility vehicles . For U.S. markets, Green Machine battery technology will increase the range and adaptability of the vehicle.
"After evaluating many potential partners, Viridi Parente was the obvious choice," said Jakob Holstein, CEO of Garia. "Not only did they have the best technology for our needs, but their technology had the most field experience. We were also aligned well on leadership and values."
Green Machine's electric utility vehicles are unlike anything currently available in the U.S. The compact design allows users to access narrow spaces such as constricted roadways, tight alleys, or compressed park or campus pathways. In addition to the traditional model, Green Machine has installed its technology into a right-hand-drive chassis from Garia that squarely fits any delivery needs.
Still dominated by fossil-fuel-powered trucks and vehicles, the supply chain remains a significant source of greenhouse gasses. In New York, transportation accounts for about 36% of the state's carbon emissions. While the nation's reliance on an efficient, reliable supply chain increases, so does the desire to transition long-haul and last-mile delivery to zero-emission vehicle options. McKinsey forecasts that the number of electric utility vehicles will grow from just 5,000 in 2018 to more than 8 million by 2030.
About Viridi Parente
Viridi Parente (Viridi) is a disruptive energy company in Buffalo, New York, that is changing the way we use energy, improving systems, communities, and lives. Viridi deploys safe battery technology into applications that have been historically dominated by fossil fuel energy sources. Its innovative architecture is constructed from materials used for aerospace and military applications and is the only design in the market that can be safely installed and operated in nearly any environment or location. Through its subsidiary, Green Machine Equipment, Viridi is bringing quiet, fully renewable mobile energy solutions to products in construction equipment, waste disposal, last-mile delivery, and other portable industrial markets. Through its subsidiary, Volta Energy Products, Viridi brings stationary, point-of-use storage technology that is safe, locatable, and reliable to industrial, medical, commercial, municipal, and residential building applications. Learn more at: www.viridiparente.com .
About Garia A/S
Garia is a manufacturer of utility vehicles, premium golf, and leisure cars. Founded in 2005 by Anders Lynge, Garia is privately held by Lars Larsen Group and headquartered in Denmark with a subsidiary in the U.S.
In 2015, with ten years of experience in the luxury electric vehicle market, Garia embarked on an entirely new journey: the Garia Utility. A compact electric utility vehicle that combines reliability, ergonomics, and zero emissions with comfort, functionality, and thoughtful design. Made of high-quality European components, the Garia Utility is one of a kind.
Learn more about the Garia Utility at gariautility.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
